CRIS Curis: Earnings per share for the trailing year

Curis, Inc. is developing innovative cancer therapies, relying on grants and partnership deals. The current YoY TTM EPS growth trend demonstrates profit dynamics, while 90.60 reflects the latest level of the metric. Future capital is based on the market launch of drugs against lymphomas and leukemias, and medium-term prospects depend on the results of phase II clinical trials.
CRIS (Curis): analytical breakdowns and indicator data

For Curis, Inc. (CRIS), whose success is driven by oncology clinical trial results regardless of GDP cycles, the rolling annual EPS change serves as an indicator of fundamental value. This metric calculates the percentage difference in earnings per share over the last 12 months relative to the same period last year, allowing investors to filter out market noise and assess the real monetization trend of the company's developments.